DK0732929T3 - Terapeutisk anvendelse af cis-element-afledere in vivo - Google Patents

Terapeutisk anvendelse af cis-element-afledere in vivo

Info

Publication number
DK0732929T3
DK0732929T3 DK95900450T DK95900450T DK0732929T3 DK 0732929 T3 DK0732929 T3 DK 0732929T3 DK 95900450 T DK95900450 T DK 95900450T DK 95900450 T DK95900450 T DK 95900450T DK 0732929 T3 DK0732929 T3 DK 0732929T3
Authority
DK
Denmark
Prior art keywords
endogenous
decoys
binding
provides
therapeutic use
Prior art date
Application number
DK95900450T
Other languages
English (en)
Inventor
Victor J Dzau
Gary H Gibbons
Ryuichi Morishita
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22509818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0732929(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK0732929T3 publication Critical patent/DK0732929T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95900450T 1993-10-29 1994-10-28 Terapeutisk anvendelse af cis-element-afledere in vivo DK0732929T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14471793A 1993-10-29 1993-10-29
PCT/US1994/012339 WO1995011687A1 (en) 1993-10-29 1994-10-28 Therapeutic use of cis-element decoys in vivo

Publications (1)

Publication Number Publication Date
DK0732929T3 true DK0732929T3 (da) 2008-09-01

Family

ID=22509818

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95900450T DK0732929T3 (da) 1993-10-29 1994-10-28 Terapeutisk anvendelse af cis-element-afledere in vivo

Country Status (8)

Country Link
US (5) US6774118B1 (da)
EP (3) EP1340505A3 (da)
AT (1) ATE395065T1 (da)
DE (1) DE69435100D1 (da)
DK (1) DK0732929T3 (da)
ES (1) ES2307293T3 (da)
PT (1) PT732929E (da)
WO (1) WO1995011687A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340505A3 (en) * 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US6034234A (en) * 1994-11-17 2000-03-07 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and anticancer agent containing the same as active ingredient
EP0824918B1 (en) 1995-05-12 2007-03-28 AnGes MG, Inc. REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB
US6946246B1 (en) * 1997-04-08 2005-09-20 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Production of functional proteins: balance of shear stress and gravity
AU5329599A (en) * 1998-07-30 2000-02-21 University Of South Florida Method for the modulation of function of transcription factors
CA2300328A1 (en) 1999-09-14 2001-03-14 Cardiogene Gentherap. Systeme Ag Modulating transcription of genes in vascular cells
CA2420724A1 (en) * 2000-08-30 2002-03-07 North Carolina State University Transgenic plants containing molecular decoys that alter protein content therein
US20030055014A1 (en) * 2000-12-14 2003-03-20 Bratzler Robert L. Inhibition of angiogenesis by nucleic acids
EP1690544B1 (en) 2001-02-20 2017-09-13 AnGes MG, Inc. Pharmaceutical composition containing decoy and method of using the same
DE10148828B4 (de) * 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
DE60231063D1 (de) * 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
US20030224992A1 (en) * 2002-03-15 2003-12-04 Praecis Pharmaceuticals Inc. Transcription factor modulators and uses thereof
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
JP4255123B2 (ja) 2002-04-26 2009-04-15 アンジェスＭｇ株式会社 転写ｄｎａ結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド（ｃｄｏｄｎ）
DE10240417A1 (de) * 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
DE10242319A1 (de) * 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
US20040266712A1 (en) * 2003-04-08 2004-12-30 Mcevoy Leslie M. Selective inhibition of vascular smooth muscle cell proliferation
WO2005035547A2 (en) * 2003-10-06 2005-04-21 Corgentech, Inc. E2f oligonucleotide decoy molecules
WO2005055804A2 (en) 2003-12-02 2005-06-23 Musc Foundation For Research Development Methods and compositions for diagnosing epithelial cell cancer
US7927873B2 (en) * 2003-12-19 2011-04-19 University Of Cincinnati Polyamides for nucleic acid delivery
WO2005079217A2 (en) * 2003-12-19 2005-09-01 University Of Cincinnati Oligonucleotide decoys and methods of use
US7981616B2 (en) 2004-02-27 2011-07-19 Musc Foundation For Research Development Enhanced detection of RNA using a panel of truncated gene-specific primers for reverse transcription
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
US20060068418A1 (en) 2004-07-09 2006-03-30 Godfrey Tony E Identification of markers in lung and breast cancer
US20060293264A1 (en) * 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
JP4921975B2 (ja) 2004-10-22 2012-04-25 アンジェスＭｇ株式会社 キメラ（ダブル）デコイ
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20060234973A1 (en) * 2005-04-14 2006-10-19 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof
CA2614295A1 (en) * 2005-06-06 2006-12-14 Anges Mg, Inc. Transcription factor decoy
WO2007071069A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
JPWO2007072909A1 (ja) 2005-12-22 2009-06-04 アンジェスＭｇ株式会社 新規オリゴヌクレオチド及びそれから成るＮＦ−κＢデコイ
US8501478B2 (en) * 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
JP5384120B2 (ja) 2007-02-16 2014-01-08 アンジェスＭｇ株式会社 歯周病、及び外科手術による歯槽骨欠損の治療剤
EP3199635B1 (en) 2007-05-11 2019-02-06 Adynxx, Inc. Gene expression and pain
WO2009117484A2 (en) 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
US20110092438A1 (en) 2008-03-28 2011-04-21 Angesmg, Inc. Composition for external application comprising transcription factor decoy as active ingredient
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
EP2846839B1 (en) 2012-05-10 2019-02-20 Adynxx, Inc. Formulations for the delivery of active ingredients
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
WO2015031628A1 (en) * 2013-08-28 2015-03-05 Oregon Health & Science University Synthetic oligonucleotides for detection of nucleic acid binding proteins
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
EP3366773A4 (en) * 2015-10-23 2019-06-12 Rena Therapeutics Inc. NUCLEIC ACID COMPLEX
WO2018067165A1 (en) * 2016-10-07 2018-04-12 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) * 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
WO1991011535A1 (en) * 1990-01-30 1991-08-08 Childrens Hospital Of Los Angeles Inhibition of transcription by double-stranded oligonucleotides
US5683985A (en) 1991-04-18 1997-11-04 The Salk Institute For Biological Studies Oligonucleotide decoys and methods relating thereto
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
ATE221913T1 (de) * 1991-08-23 2002-08-15 Univ Nebraska Verfahren und zusammensetzungen für zelluläre reprogrammierung
WO1993014768A1 (en) * 1992-01-27 1993-08-05 The Trustees Of The University Of Pennsylvania Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function
AU3609693A (en) * 1992-01-29 1993-09-01 Duke University Method of assaying for the oncogenic state of cells
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
JP3633616B2 (ja) * 1992-10-29 2005-03-30 トポターゲット ユーケー リミテッド 転写因子ｄｐ−１
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
AU683626B2 (en) * 1993-10-29 1997-11-20 Shunichi Shiozawa Antagonistic inhibitor for the proliferation of mesenchymal cells
EP1340505A3 (en) 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
EP0824918B1 (en) * 1995-05-12 2007-03-28 AnGes MG, Inc. REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB
US6890909B1 (en) * 1997-07-04 2005-05-10 Fujisawa Pharmaceutical Co., Ltd. Brain-protective agent
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
EP1690544B1 (en) * 2001-02-20 2017-09-13 AnGes MG, Inc. Pharmaceutical composition containing decoy and method of using the same
AU2002349402B2 (en) * 2001-11-22 2008-01-31 Anges Mg, Inc. Compositions inhibiting rejection in organ transplantation and method of using the same
DE60231063D1 (de) * 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
US20060135449A1 (en) * 2002-03-29 2006-06-22 Yoshiki Sawa Decoy compositions for treating and preventing brain diseases and disorders
JPWO2003099339A1 (ja) * 2002-05-29 2005-09-22 アンジェスＭｇ株式会社 炎症性疾患を処置および予防するためのデコイ組成物
US20040191328A1 (en) * 2002-12-31 2004-09-30 Warrell Raymond P. Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
US20040191779A1 (en) * 2003-03-28 2004-09-30 Jie Zhang Statistical analysis of regulatory factor binding sites of differentially expressed genes
EP1462111A1 (en) * 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Composition for inducing immunotolerance
WO2005051229A2 (en) * 2003-11-24 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US7378509B2 (en) * 2003-12-02 2008-05-27 Anesiva, Inc. NF-kappaB oligonucleotide decoy molecules
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides

Also Published As

Publication number Publication date
EP0732929A4 (en) 2001-11-14
US6774118B1 (en) 2004-08-10
EP0732929A1 (en) 1996-09-25
EP1340505A2 (en) 2003-09-03
US20030186922A1 (en) 2003-10-02
EP1350514A2 (en) 2003-10-08
EP1350514A3 (en) 2004-07-07
US20020052333A1 (en) 2002-05-02
EP1340505A3 (en) 2004-07-14
US20040229833A1 (en) 2004-11-18
US20020128217A1 (en) 2002-09-12
ES2307293T3 (es) 2008-11-16
PT732929E (pt) 2008-08-26
DE69435100D1 (de) 2008-06-26
ATE395065T1 (de) 2008-05-15
US6821956B2 (en) 2004-11-23
EP0732929B1 (en) 2008-05-14
WO1995011687A1 (en) 1995-05-04

Similar Documents

Publication Publication Date Title
DK0732929T3 (da) Terapeutisk anvendelse af cis-element-afledere in vivo
RU2164944C1 (ru) Способ изменения генетических свойств организма
AU2989300A (en) Controlling protein levels in eucaryotic organisms
EE9900413A (et) Medikamentide kontrollitud väljutamine silma eeskambrisse
EP1140971A4 (en) ANTISENS MODULATION OF NEW ANTI-APOPTOTIC BCL-2-LIKE PROTEINS
PT1038022E (pt) Avaliacao de doencas relacionadas com o virus papiloma humano
DK1061940T3 (da) Anvendelse af follistatin til fremstilling af et medikament til behandling af muskelrelaterede lidelser
NO20006078L (no) N-bundete sulfen-amider av N-heterocykliske karboksylsyrer eller karboksylsyre-isostere
CA2098849A1 (en) Control of gene expression by ionizing radiation
DE69804927D1 (de) Vorrichtung zur Behandlung von Tachykardien auf der Basis von ventrikulären Stabilität
HUP9603484A2 (hu) Gyógyászati készítmények és eljárás ingerületátvitel befolyásolására
BR9508308A (pt) Derivados de benzoíla e sintese dos mesmos
DK0386734T3 (da) Immunogene regioner på E-7-proteinet af humant papillomavirus type 16
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DE69902523T2 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
NO924309L (no) Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna
DE69837564D1 (de) Azaheterozyklischederivate zur behandlung von haarausfall und neurologischer krankheiten
NO308396B1 (no) FremgangsmÕte ved fremstilling av substanser av polypeptidnatur
DK160947C (da) Gen-udtrykkelsessystem
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
ATE148109T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
DK0950416T3 (da) Anvendelse af TCF-II til behandling af cancerrelateret tab af kropsvægt, anæmi og TNF-forhöjelse
Idrissou et al. Exciting history of Tip60 and its companions in carcinogenesis across the heterochromatin landscapes
Amand et al. Cadherins and catenins, Wnts and SOXs: embryonic patterning in Xenopus